Pharmaceutical News
The US Department of Health and Human Services (HHS), through the Centers for Medicare and Medicaid Services (CMS), has announced the selection of 15 new drugs covered under Medicare Part D for price negotiations. 17 January 2025
US pharma major Eli Lilly is to buy the PI3Kα inhibitor program STX-478 from Scorpion Therapeutics, a private US biotech developing small molecule precision oncology therapies. 14 January 2025
Shares of USA-based Intra-Cellular Therapies leapt almost 36% to $128.85 in pre-marker activity today, as rumors of a takeover bid were confirmed. 13 January 2025
Exclusive
Company Spotlight
"Swedish drug developer Orexo is an emerging specialty pharma company developing improved treatments using proprietary drug delivery technology."
Most Read
7 January 2025
6 January 2025
In Brief
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Jeraygo (aprocitentan) to treat hypertension (high blood pressure) in adults whose blood pressure cannot be adequately controlled by at least three other medicines (also known as resistant hypertension). 17 January 2025
Mergers and Acquisitions
India’s Sun Pharmaceutical Industries announced that its subsidiary, Taro Pharmaceuticals, has entered into an agreement to acquire a 100 per cent stake in Antibe Therapeutics, a clinical-stage biotechnology company based in Ontario, Canada. 20 January 2025
14 January 2025
13 January 2025
13 January 2025
6 January 2025
Editor's Pick
Boardroom
UK clinical-stage specialty pharma firm Actimed Therapeutics has appointed Dr Fabio Dorigotti as chief medical officer (CMO) following the retirement of previous CMO, Dr Frank Misselwitz. 16 January 2025
Boston, USA-based Verastem Oncology today announced the appointment of Matthew Ros as chief operating officer (COO). 15 January 2025
French independent pharma company Servier says it has appointed David Lee to its executive committee as executive vice president for the United States, effective January 1, 2025. 13 January 2025
Medicines Discovery Catapult (MDC), the UK government-backed life sciences service dedicated to driving productivity and impact in drug R&D, has strengthened its executive team with the appointment of a chief commercial officer (CCO) and its first managing director (MD). 13 January 2025
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze